Ascendis Pharma A/S - ADR (ASND) Company Profile & Statistics

Ascendis Pharma A/S - ADR
ASND
(Nasdaq - US)
Open
123.66
-0.72 (-0.58%)
in:usd•As of: Nov 21, 2024 13:43 UTC -5
Open
123.25
High
124.45
Low
122.48

About Ascendis Pharma A/S - ADR

CEO

Jan M¿ller Mikkelsen

Headquarters

tuborg boulevard 12

hellerup, g7 2900, denmark

Auditor

Deloitte Statsautoriseret Revisionspartnerselskab

Employees

879

Share Holders

N/A

Website

www.ascendispharma.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark.

Ascendis Pharma A/S - ADR Statistics

Valuation Measures

Market Capitalization ²	7.50B
Enterprise Value	7.86B
Enterprise Value/EBITDA (ttm)	-24.40
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	N/A
Price to Sales (ttm)	21.31
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	81.70%
Operating Margin (ttm)	-130.33%
Profit Margin (ttm)	-168.65%
Return on Equity (ttm)	N/A
Return on Invested Capital (ttm)	1576.18%
Return on Assets (ttm)	-48.77%

Income Statement

Revenue (ttm)	355.13M
Revenue Per Share (ttm)	N/A
Gross Profit (ttm)	301.30M
EBITDA (ttm)³	-322.32M
Net Income Avi to Common (ttm)	-462.17M
Diluted EPS (ttm)	-8.08

Share Statistics

Beta (5Y Monthly)	0.66
52-Week Change	31.89%
S&P500 52-Week Change	31.23%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	N/A
Dividend Yield	0.00%
Float ⁴	36.38M
% Held by Insiders	40.00%
% Held by Institutions	N/A

Balance Sheet

Total Cash (mrq)	687.82M
Total Cash Per Share (mrq)	N/A
Total Debt (mrq)	1.05B
Total Debt/Equity (mrq)	-983.36%
Current Ratio (mrq)	1.16%
Quick Ratio (mrq)	0.84%
Book Value Per Share (mrq)	-1.79

Cash Flow

Operating Cash Flow Per Share (ytd)	-4.19
Free Cash Flow (ytd)	-240.94M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Ascendis Pharma A/S - ADR

Trade With A Regulated Broker